Basilea Pharmaceutica AG (SWX: BSLN)

Market Cap	552.12M
Revenue (ttm)	149.02M
Net Income (ttm)	-652.00K
Shares Out	12.12M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	14.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,669
Open	44.80
Previous Close	45.55
Day's Range	44.50 - 45.20
52-Week Range	32.00 - 48.55
Beta	0.70
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumoni...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 147
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: BSLN

Financial Performance

In 2023, KURN's revenue was 33.56 million, an increase of 86.61% compared to the previous year's 17.99 million. Losses were -13.73 million, -5.95% less than in 2022.